<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10468294</article-id><article-id pub-id-type="pmc">2363131</article-id><article-id pub-id-type="pii">6690595</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690595</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bedane</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Geoffrois</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lesimple</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Delaunay</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine, Institut Bergoni&#x000e9;, 180 rue de Saint-Gen&#x000e8;s, Bordeaux Cedex, 33076, France</aff><aff id="aff2"><label>2</label>Department of Dermatology, CHU Dupuytren, Limoges, France</aff><aff id="aff3"><label>3</label>Department of Medicine, Centre Alexis Vautrin, Comprehensive Cancer Center, Nancy, France</aff><aff id="aff4"><label>4</label>Department of Medicine, Centre Eug&#x000e8;ne Marquis, Comprehensive Cancer Center, Rennes, France</aff><aff id="aff5"><label>5</label>Department of Oncodermatology, CHU Pellegrin, Bordeaux, France</aff><pub-date pub-type="ppub"><month>08</month><year>1999</year></pub-date><volume>80</volume><issue>11</issue><fpage>1767</fpage><lpage>1769</lpage><history><date date-type="received"><day>03</day><month>06</month><year>1998</year></date><date date-type="rev-recd"><day>09</day><month>10</month><year>1998</year></date><date date-type="accepted"><day>04</day><month>11</month><year>1998</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><kwd-group><kwd>melanoma</kwd><kwd>immunotherapy</kwd><kwd>adjuvant treatment</kwd><kwd>interferon alpha</kwd><kwd>toxicity</kwd></kwd-group></article-meta></front></article>


